Tyra Biosciences, Inc. Operating Cash Flow
Tyra Biosciences, Inc. (TYRA) reported Operating Cash Flow of -$63.65 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- Tyra Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$31.08M.
- Tyra Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$32.57M.
- Tyra Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$23.62M.
- Tyra Biosciences, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$22.38M.
- Tyra Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$95.14M.
- Tyra Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$69.77M.
- Tyra Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$50.14M.
- Tyra Biosciences, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$50.28M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$31.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$63.65M 10-Q · filed 2026-08-04 | -$87.27M derived: sum of 3 quarters · filed 2026-08-04 | -$109.65M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | -$32.57M 10-Q · filed 2026-05-13 | -$56.20M derived: sum of 2 quarters · filed 2026-05-13 | -$78.58M derived: sum of 3 quarters · filed 2026-05-13 | -$102.25M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | -$23.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$46.00M derived: sum of 2 quarters · filed 2026-03-02 | -$69.68M derived: sum of 3 quarters · filed 2026-08-04 | -$95.14M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$22.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$46.06M derived: sum of 2 quarters · filed 2026-08-04 | -$71.52M 10-Q · filed 2025-11-05 | -$91.11M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | -$23.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$49.14M 10-Q · filed 2026-08-04 | -$68.73M derived: sum of 3 quarters · filed 2026-08-04 | -$86.63M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | -$25.46M 10-Q · filed 2026-05-13 | -$45.05M derived: sum of 2 quarters · filed 2026-05-13 | -$62.95M derived: sum of 3 quarters · filed 2026-05-13 | -$73.20M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$19.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$37.49M derived: sum of 2 quarters · filed 2026-03-02 | -$47.75M derived: sum of 3 quarters · filed 2026-03-02 | -$69.77M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$17.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$28.16M derived: sum of 2 quarters · filed 2025-11-05 | -$50.18M 10-Q · filed 2025-11-05 | -$63.72M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | -$10.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$32.29M 10-Q · filed 2025-08-14 | -$45.82M derived: sum of 3 quarters · filed 2025-08-14 | -$62.96M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$22.03M 10-Q · filed 2025-05-08 | -$35.56M derived: sum of 2 quarters · filed 2025-05-08 | -$52.70M derived: sum of 3 quarters · filed 2025-05-08 | -$62.32M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$13.53M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$30.68M derived: sum of 2 quarters · filed 2025-03-27 | -$40.29M derived: sum of 3 quarters · filed 2025-03-27 | -$50.14M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$17.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$26.76M derived: sum of 2 quarters · filed 2024-11-07 | -$36.61M 10-Q · filed 2024-11-07 | -$48.59M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$9.62M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | -$19.46M 10-Q · filed 2024-08-07 | -$31.44M derived: sum of 3 quarters · filed 2024-08-07 | -$43.65M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | -$9.85M 10-Q · filed 2024-05-09 | -$21.83M derived: sum of 2 quarters · filed 2024-05-09 | -$34.04M derived: sum of 3 quarters · filed 2024-05-09 | -$51.21M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$11.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$24.19M derived: sum of 2 quarters · filed 2024-03-19 | -$41.36M derived: sum of 3 quarters · filed 2024-03-19 | -$50.28M 10-K · filed 2024-03-19 |
| 2022-09-30 | -$12.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$29.38M derived: sum of 2 quarters · filed 2023-11-07 | -$38.30M 10-Q · filed 2023-11-07 | -$47.33M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$17.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$26.09M 10-Q · filed 2023-08-10 | -$35.12M derived: sum of 3 quarters · filed 2023-08-10 | -$40.70M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$8.93M 10-Q · filed 2023-05-04 | -$17.95M derived: sum of 2 quarters · filed 2023-05-04 | -$23.53M derived: sum of 3 quarters · filed 2023-05-04 | -$27.99M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | -$9.03M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$14.61M derived: sum of 2 quarters · filed 2023-03-22 | -$19.07M derived: sum of 3 quarters · filed 2023-03-22 | -$23.75M 10-K · filed 2023-03-22 |
| 2021-09-30 | -$5.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$10.04M derived: sum of 2 quarters · filed 2022-11-03 | -$14.72M 10-Q · filed 2022-11-03 | -$17.25M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | -$4.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$9.14M 10-Q · filed 2022-08-04 | -$11.67M derived: sum of 3 quarters · filed 2022-08-04 | |
| 2021-03-31 | -$4.68M 10-Q · filed 2022-05-05 | -$7.21M derived: sum of 2 quarters · filed 2022-05-05 | ||
| 2020-12-31 | -$2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | -$7.76M 10-K · filed 2022-03-03 | ||
| 2020-09-30 | -$5.23M 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |